Stock comparison
LeMaitre Vascular
10x Genomics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
TXG
10x Genomics
Market cap
$3.01B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | TXG | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 33F | LMAT |
| Benjamin Graham | 89A | 54D | LMAT |
| Philip Fisher | 81C | 34F | LMAT |
| Peter Lynch | 67B | 15F | LMAT |
| Joel Greenblatt | 56D | 0F | LMAT |
| Charlie Munger | 68D | 29F | LMAT |
| Terry Smith | 69D | 31F | LMAT |
Side-by-side metrics
| Metric | LMAT | TXG |
|---|---|---|
| Market cap | $2.23B | $3.01B |
| P/E (TTM) | 37.1x | - |
| EV/EBIT | 36.6x | - |
| ROIC (TTM) | 9.43% | -4.24% |
| Gross margin | 72.39% | 69.6% |
| Net margin | 24.35% | -3.55% |
| Revenue CAGR 5y | 12.75% | 7.0% |
| EPS CAGR 5y | 19.04% | - |
| Debt / Equity | 0.5x | 0.1x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- ROIC (TTM)9.43%vs -4.24%+145%
- Net margin24.35%vs -3.55%+115%
- Dividend yield0.84%vs 0.0%+100%
- Revenue CAGR 5y12.75%vs 7.0%+45%
TXG leads on
- EV/EBIT-vs 36.6x+157%
- P/E (TTM)-vs 37.1x+131%
- Debt / Equity0.1xvs 0.5x+79%
- Market cap$3.01Bvs $2.23B+26%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.